Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 1/2021

Open Access 01-02-2021 | Atopic Dermatitis | Brief Report

Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia

Authors: David Luk, Kam Lun Ellis Hon, Maria Victoria C. Dizon, Kin-Fon Leong, Yong-Kwang Tay, Mark Jean-Aan Koh, Nisha Suyien Chandran, Siriwan Wananukul, Susheera Chatproedprai, Thomas Luger

Published in: Dermatology and Therapy | Issue 1/2021

Login to get access

Abstract

Introduction

There is some evidence to suggest that the prevalence of atopic dermatitis (AD) in Asia is rising. We have therefore developed an algorithm for the topical treatment of AD throughout South and East Asia for use by primary care physicians, pediatricians and dermatologists.

Methods

Nine AD experts from South and East Asia and one from Europe developed the algorithm based upon treatment guidelines, relevant literature and local treatment practices. The algorithm outlines current best practice for the use of emollients, topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI), with the intention of simplifying the treatment regimen of mild-to-moderate AD in South and East Asia.

Results

Patients with AD should bathe and cleanse affected skin to remove crusts and scales daily. Emollients should also be applied daily as a maintenance treatment. When selecting appropriate topical anti-inflammatory treatment for AD flares, several factors should be taken into consideration, including the patient’s age, attitude to treatment options and site of AD lesions. Given the concerns regarding the risk of skin atrophy with use of TCS, a TCI should be used to treat AD lesions in sensitive skin areas: pimecrolimus is recommended for mild-to-moderate AD in these locations, while tacrolimus should be considered for moderate and severe cases. Either pimecrolimus or tacrolimus is recommended for flares in other, non-sensitive body locations. A proactive or intermittent maintenance treatment strategy involving regular emollient use and twice-weekly application of a TCI to previously affected areas is encouraged to reduce the risk of flares.

Conclusions

The algorithm proposed here is intended to simplify the topical treatment of mild-to-moderate AD in daily practice in South and East Asian countries.
Literature
1.
2.
Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387:1109–22.PubMed
3.
Noda S, Suarez-Farinas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136:1254–64.PubMed
4.
Cheok S, Yee F, Song Ma JY, et al. Prevalence and descriptive epidemiology of atopic dermatitis and its impact on quality of life in Singapore. Br J Dermatol. 2018;178:276–7.PubMed
5.
Goh YY, Keshavarzi F, Chew YL. Prevalence of atopic dermatitis and pattern of drug therapy in malaysian children. Dermatitis. 2018;29:151–61.PubMed
6.
Yu JS, Lee CJ, Lee HS, et al. Prevalence of atopic dermatitis in Korea: analysis by using national statistics. J Korean Med Sci. 2012;27:681–5.PubMedPubMedCentral
7.
Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLoS ONE. 2012;7:e39803.PubMedPubMedCentral
8.
Tay YK, Kong KH, Khoo L, Goh CL, Giam YC. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol. 2002;146:101–6.PubMed
9.
Kabashima K, Otsuka A, Nomura T. Linking air pollution to atopic dermatitis. Nat Immunol. 2016;18:5–6.PubMed
10.
Hidaka T, Ogawa E, Kobayashi EH, et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol. 2017;18:64–73.PubMed
11.
Chen H, Common JE, Haines RL, et al. Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations. Br J Dermatol. 2011;165:106–14.PubMed
12.
Meng L, Wang L, Tang H, et al. Filaggrin gene mutation c.3321delA is associated with various clinical features of atopic dermatitis in the Chinese Han population. PLoS ONE. 2014;9:e98235.PubMedPubMedCentral
13.
Chan YC, Tay YK, Sugito TL, et al. A study on the knowledge, attitudes and practices of Southeast Asian dermatologists in the management of atopic dermatitis. Ann Acad Med Singapore. 2006;35:794–803.PubMed
14.
Leung TN, Hon KL. Eczema therapeutics in children: what do the clinical trials say? Hong Kong Med J. 2015;21:251–60.PubMed
15.
Chen HY, Lin YH, Su IH, Chen YC, Yang SH, Chen JL. Investigation on Chinese herbal medicine for primary dysmenorrhea: implication from a nationwide prescription database in Taiwan. Complement Ther Med. 2014;22:116–25.PubMed
16.
Zhu Y, Shi H, Wang Q, et al. Association between nine types of TCM constitution and five chronic diseases: a correspondence analysis based on a sample of 2,660 participants. Evid Based Complement Alternat Med. 2017;2017:9439682.PubMedPubMedCentral
17.
Hon KL, Leung AKC, Leung TNH, Lee VWY. Complementary, alternative and integrative medicine for childhood atopic dermatitis. Recent Pat Inflamm Allergy Drug Discov. 2017;11:114–24.PubMed
18.
Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24:985–94.PubMed
19.
Mueller SM, Itin P, Vogt DR, et al. Assessment of “corticophobia” as an indicator of non-adherence to topical corticosteroids: a pilot study. J Dermatolog Treat. 2017;28:104–11.PubMed
20.
Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012a;26:1176–93.PubMed
21.
Sidbury R, Tom WL, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71:1218–33.
22.
Tay YK, Chan YC, Chandran NS, et al. Guidelines for the management of atopic dermatitis in Singapore. Ann Acad Med Singapore. 2016;45:439–50.PubMed
23.
Leung TNH, Chow CM, Chow MPY, et al. Clinical guidelines on management of atopic dermatitis in children. Hong Kong J Paediatr. 2013;18:96–104.
24.
Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26:1045–60.PubMed
25.
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327–49.
26.
Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32:657–82.PubMed
27.
Reda AM, Elgendi A, Ebraheem AI, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019;30:366–73.PubMed
28.
Eichenfield LF, Boguniewicz M, Simpson EL, et al. Translating atopic dermatitis management guidelines into practice for primary care providers. Pediatrics. 2015;136:554–65.PubMed
29.
Werfel T, Ballmer-Weber B, Eigenmann PA, et al. Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN. Allergy. 2007;62:723–8.PubMed
30.
Hon KL, Leung AK, Barankin B. Barrier repair therapy in atopic dermatitis: an overview. Am J Clin Dermatol. 2013;14:389–99.PubMed
31.
Hon KL, Kung JSC, Ng WGG, Leung TF. Emollient treatment of atopic dermatitis: latest evidence and clinical considerations. Drugs Context. 2018;7:212530.PubMedPubMedCentral
32.
Saeki H. Management of atopic dermatitis in Japan. J Nippon Med School. 2017;84:2–11.
33.
Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22:850–9.PubMedPubMedCentral
34.
Williams MR, Gallo RL. Evidence that human skin microbiome dysbiosis promotes atopic dermatitis. J Invest Dermatol. 2017;137:2460–1.PubMedPubMedCentral
35.
Hon KL, Tsang KY, Kung JS, Leung TF, Lam CW, Wong CK. Clinical Signs, staphylococcus and atopic eczema-related seromarkers. Molecules. 2017;22(2):291.
36.
Chow S, Seow CS, Dizon MV, et al. A clinician’s reference guide for the management of atopic dermatitis in Asians. Asia Pac Allergy. 2018;8:e41.PubMedPubMedCentral
37.
Katayama I, Aihara M, Ohya Y, et al. Japanese guidelines for atopic dermatitis 2017. Allergol Int. 2017;66:230–47.PubMed
38.
39.
Saeki H, Nakahara T, Tanaka A, et al. Clinical practice guidelines for the management of atopic dermatitis 2016. J Dermatol. 2016;43:1117–45.PubMed
40.
Kim JE, Kim HJ, Lew BL, et al. Consensus guidelines for the treatment of atopic dermatitis in Korea (Part I): general management and topical treatment. Ann Dermatol. 2015;27:563–77.PubMedPubMedCentral
41.
42.
Mylan. Elidel 1% Summary of Product Characteristics (Brazil). Mylan. November 2018.
43.
Mylan. Elidel 1% Summary of Product Characteristics (India). Mylan. May 2018.
44.
Mylan. Elidel 1% Summary of Product Characteristics (Thailand). Mylan. April 2008.
45.
46.
Mylan. Elidel 1% Summary of Product Characteristics (New Zealand). Mylan. April 2018.
47.
Mylan. Elidel 1% Summary of Product Characteristics (Philippines). Mylan. April 2017.
48.
49.
Mylan. Elidel 1% Summary of Product Characteristics (Indonesia). Mylan. April 2008.
50.
Broeders JA, Ahmed Ali U, Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol. 2016;75(410–9):e3.
51.
Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol. 2017;153:1036–42.PubMed
52.
Lee JY, Her Y, Kim CW, Kim SS. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Ann Dermatol. 2015;27:499–506.PubMedPubMedCentral
53.
Kojima R, Fujiwara T, Matsuda A, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol. 2013;30:29–35.PubMed
54.
Hon KL, Tsang YC, Pong NH, et al. Correlations among steroid fear, acceptability, usage frequency, quality of life and disease severity in childhood eczema. J Dermatolog Treat. 2015;26:418–25.PubMed
55.
Muller SM, Tomaschett D, Euler S, Vogt DR, Herzog L, Itin P. Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study. Dermatology. 2016;232:444–52.PubMed
56.
Hussain Z, Sahudin S, Thu HE, Shuid AN, Bukhari SN, Kumolosasi E. Recent advances in pharmacotherapeutic paradigm of mild to recalcitrant atopic dermatitis. Crit Rev Ther Drug Carrier Syst. 2016;33:213–63.PubMed
57.
58.
59.
Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14:163–78.PubMedPubMedCentral
60.
Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.PubMedPubMedCentral
61.
Cai SC, Li W, Tian EA, Allen JC, Tey HL. Topical calcineurin inhibitors in eczema and cancer association: a cohort study. J Dermatolog Treat. 2016;27:531–7.PubMed
62.
Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83:375–81.PubMed
63.
Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116–32.
64.
Hon KL, Leong KF, Leung TN, Leung AK. Dismissing the fallacies of childhood eczema management: case scenarios and an overview of best practices. Drugs Context. 2018;7:212547.PubMedPubMedCentral
65.
Gollnick H, Luger T, Freytag S, Brautigam M, group Ss. StabiEL: stabilization of skin condition with Elidel—a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid. J Eur Acad Dermatol Venereol. 2008;22:1319–25.
66.
Reitamo S, Rustin M, Harper J, et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008;159:942–51.
67.
Langa Y, Van der Merwe E. Atopic dermatitis: tacrolimus vs. topical corticosteroid use. South Afri Fam Pract. 2011;53:340–6.
68.
Svensson A, Chambers C, Gånemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin. 2011;27:1395–406.PubMed
69.
Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51:515–25.
70.
Ee S, Tay YK, Chu CY, Hon KLE, Leong KF, Wananukul S. A study on the knowledge, attitudes, and practices of Asian dermatologists in the management of atopic dermatitis. Dermatol Sin. 2020;38:67–80.
71.
Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63:742–50.
72.
Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002;110:277–84.PubMed
73.
Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2.PubMed
74.
Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135:597–606.PubMed
75.
Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26:551–8.PubMed
76.
Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics. 2008;122:e1210–8.PubMed
77.
Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies. J Dermatolog Treat. 2010;21:34–44.PubMed
78.
Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159:1348–56.
79.
Kim KH, Kono T. Overview of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas. Int J Dermatol. 2011;50:1153–61.PubMed
80.
Eichenfield LF, Lucky AW, Langley RG, et al. Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. Int J Dermatol. 2005;44:70–5.PubMed
81.
Lynde C, Barber K, Claveau J, et al. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg. 2005;8(Suppl 5):1–9.
82.
Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26:306–15.PubMedPubMedCentral
83.
Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol. 2004;114:137–43.PubMed
84.
Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans’ cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol. 2001;107:345–52.PubMed
85.
Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol. 2004;122:673–84.PubMed
86.
Meingassner JG, Kowalsky E, Schwendinger H, Elbe-Burger A, Stutz A. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol. 2003;149:853–7.PubMed
87.
Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Burger A. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2005;115:1276–83.PubMed
88.
Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus—an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004;13:721–30.PubMed
89.
Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269:29–35.PubMed
90.
Weiss HM, Fresneau M, Moenius T, Stuetz A, Billich A. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos. 2008;36:1812–8.PubMed
91.
Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol. 2005;124:695–9.PubMed
92.
Hoeger PH, Lee KH, Jautova J, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol. 2009;160:415–22.PubMed
93.
Zuberbier T, Brautigam M. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol. 2008;22:718–21.PubMed
94.
Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7:121–31.PubMed
95.
Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;157:954–9.PubMed
96.
Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Gold LS. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy. 2016;8:853–66.PubMed
97.
Hon KL, Leung AKC, Leung TNH, Lee VWY. Investigational drugs for atopic dermatitis. Expert Opin Investig Drugs. 2018;27:637–47.PubMed
98.
Suga H, Sato S. Novel topical and systemic therapies in atopic dermatitis. Immunol Med. 2019;42:84–93.PubMed
Metadata
Title
Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia
Authors
David Luk
Kam Lun Ellis Hon
Maria Victoria C. Dizon
Kin-Fon Leong
Yong-Kwang Tay
Mark Jean-Aan Koh
Nisha Suyien Chandran
Siriwan Wananukul
Susheera Chatproedprai
Thomas Luger
Publication date
01-02-2021
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2021
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-020-00467-8

Other articles of this Issue 1/2021

Dermatology and Therapy 1/2021 Go to the issue

Review

Rosacea Treatment: Review and Update

Review

Topical Probiotics in Dermatological Therapy and Skincare: A Concise Review

Review

Lessons Learned from the First Decade of Laser-Assisted Drug Delivery

Review

New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review

Original Research

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Original Research

Two-Year US Pharmacovigilance Report on Brodalumab
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits